Freedom Capital analyst Ilya Zubkov has upgraded Eli Lilly to Buy from Hold with a price target of $1,200, citing strong growth momentum. The upgrade follows a strategic $2.4 billion acquisition and optimistic financial guidance that solidifies the company's $1 trillion market valuation.
- The acquisition of Orna Therapeutics represents a major strategic push into CAR-T therapies for autoimmune disorders.
- Lilly projects robust 2026 revenue between $80 billion and $83 billion, driven by significant manufacturing investments.
- Shares increased 0.41% to $1029.22, as the company continues to outperform competitors like Novo Nordisk.